BCIRG OO6 – Adjuvant TCH for Breast Cancer presented at the SABCS 2009 by Slamon, D et al. is ready for review.
In summary, here are the findings:
The authors concluded that the addition of trastuzumab to either an anthracycline or non-anthracycline based chemotherapy regimens provides similar and significant benefit both in terms of disease free survival and overall survival and this benefit is seen in both low and high risk patients .
To view the entire Synopsis and Clinical Relevance, log on to https://www.chemoforme.com – if aren’t registered yet; the subscription is free.
